Skip to Content

Join the 'Daratumumab' group to help and get support from people like you.

Daratumumab News

Janssen Announces Darzalex (daratumumab) U.S. FDA Approval for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible

Posted 10 May 2018 by Drugs.com

HORSHAM, PA, May 7, 2018 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) in combination with Velcade (bortezomib)*, a proteasome inhibitor (PI); melphalan, an alkylating agent; and prednisone – VMP – for the treatment of patients with newly diagnosed multiple myeloma who are ine ...

Genmab Announces U.S. FDA Approval of Darzalex (daratumumab) in Combination with Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Posted 22 Jun 2017 by Drugs.com

Copenhagen, Denmark; June 16, 2017 — Genmab A/S (Nasdaq Copenhagen: GEN) announced today the U.S. Food and Drug Administration (FDA) has approved the use of Darzalex (daratumumab) in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. Darzalex is being ...

Publicly Funded Cancer Trials Gained Americans 3 Million More Years

Posted 6 Jun 2017 by Drugs.com

TUESDAY, June 6, 2017 – Public-funded trials have significantly extended the lives of people diagnosed with cancer, according to new research. SWOG, the clinical trials network funded by the U.S. National Cancer Institute (NCI), has involved more than 200,000 patient volunteers. These trials have led to approval of 14 new cancer drugs and more than 100 changes to cancer care standards. All told, ...

Darzalex (daratumumab) Approved by FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy

Posted 23 Nov 2016 by Drugs.com

HORSHAM, PA, Nov. 21, 2016 – Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration (FDA) has approved Darzalex (daratumumab) in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.1 Clinical studies have shown that Darzalex, in combination with l ...

Drug Trio Shows Major Promise Against Myeloma

Posted 6 Oct 2016 by Drugs.com

THURSDAY, Oct. 6, 2016 – Adding a newer drug to a standard treatment for advanced cases of multiple myeloma may significantly boost patients' chances of a response and even recovery, a new clinical trial finds. Of patients given the drug, called daratumumab, 43 percent had a complete response – meaning there were no signs of the cancer left. That compared with 19 percent of patients who ...

Superior Results for Myeloma Drug That's Added Earlier in Treatment

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – A recently approved immunotherapy drug for a blood cancer called multiple myeloma can provide even better benefits if patients receive it earlier in their treatment, new clinical trial results show. Darzalex (daratumumab) reduced patients' risk of cancer progression by 70 percent when added to a standard two-drug regimen for people with recurring myeloma, said lead ...

U.S. Pays Highest Prices for Cancer Meds: Study

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – The United States pays the highest prices in the world for generic and brand-name cancer drugs, a new study has found. However, as the world's wealthiest nation, the United States is better able to pay for those pricey drugs than poorer countries with somewhat lower medication prices, added study lead author Dr. Daniel Goldstein. People in China and India are much less ...

Darzalex Approved for Multiple Myeloma

Posted 16 Nov 2015 by Drugs.com

MONDAY, Nov. 16, 2015 – The injected chemotherapy drug Darzalex (daratumumab) has been approved by the U.S. Food and Drug Administration to treat people who have had at least three prior treatments for multiple myeloma, a form of blood cancer. The disease affects germ-fighting white blood cells found in bone marrow, potentially causing a weakened immune system, and problems involving the bones ...

FDA Approves Darzalex (daratumumab) for Patients with Previously Treated Multiple Myeloma

Posted 16 Nov 2015 by Drugs.com

November 16, 2015 – Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma. Multiple myeloma is a form of blood cancer that occurs in infection-fighting plasma cells (a type of ...

Ask a Question

Further Information

Related Condition Support Groups

Multiple Myeloma

Related Drug Support Groups

Darzalex

Daratumumab Patient Information at Drugs.com